BOARD OF DIRECTORS

David Schlotterbeck is CEO of Aperio, and the retired chairman and CEO of CareFusion, a leading medical technology company. From 2004 through 2009, he served as vice chairman of Cardinal Health and CEO for their clinical and medical products business segment. He joined Cardinal Health through the acquisition of Alaris Medical Systems, where he was president and CEO from 1999 through 2004. Mr. Schlotterbeck previously held executive leadership roles as president and COO of Pacific Scientific Company; president and CEO of Vitalcom, Inc.; and, executive vice president and COO of Nellcor, Inc. He holds a B.S. in electrical engineering from the General Motors Institute (Kettering University) and an M.S. in electrical engineering from Purdue University.

Thomas Bologna is president, CEO, and a member of the board of Orchid Cellmark, Inc., a leading service provider of DNA identity testing, and chairman of the board of SDIX, a public diagnostics company. Prior to joining Orchid Cellmark, Mr. Bologna was president, CEO, and a member of the board of Quorex Pharmaceuticals, a venture-backed company that he sold to Pfizer. Prior to leading Quorex, Mr. Bologna was chairman of the board, president, and CEO of Ostex International, Inc., a biotechnology company that developed and commercialized products to make disease management a reality. Prior experience includes president and CEO of Scriptgen Pharmaceuticals, Inc., a Boston biotechnology start-up company and chairman of the board, president and CEO of Gen-Probe, Inc. He took Gen-Probe public on the NASDAQ market and subsequently sold it to Chugai Pharmaceutical Co. Mr. Bologna served as president of the Becton Dickinson Diagnostic Systems Division and as a VP at the Warner Lambert Company. Mr. Bologna received his B.S. from the New York University School of Engineering and Science and his M.B.A. from the New York University Graduate School of Business Administration (Stern School of Management).

Martin Felsenthal is a partner of HLM Venture Partners. Marty was previously a general partner of Salix Ventures, where he focused on investments in health care services and health care information technology. Marty served on the boards of Vantage Oncology, US Renal Care, Ancillary Care Management, Vericare, AccentCare, Titan Health and Payerpath. At Salix, Marty was involved in helping management found a number of new businesses through platform acquisitions, including Vantage and Vericare. He also recruited more than 25 executives to the portfolio companies with whom he worked. Marty serves on the Foundation Board of California Pacific Medical Center. He received a B.A. from Princeton University and an M.B.A. from the Stanford University Graduate School of Business.

Mark Gergen has served on the Aperio board of directors since April, 2002. Mr. Gergen is senior vice president of corporate development at Amylin Pharmaceuticals. Prior to Amylin, Mr. Gergen was an executive consultant to a number of life science companies. He has held the positions of executive vice president of CardioNet, Inc., chief restructuring officer and acting CEO of Advanced Tissue Sciences, Inc., having previously served as senior vice president, chief financial and development officer as well as vice president, corporate development and general counsel for that company. He has held various legal and corporate development roles at Premier, Inc., Medtronic, Inc., and Jostens, Inc. Mr. Gergen has a J.D. from the University of Minnesota Law School and a B.A. in Business from Minot State University. He presently serves on the boards of several private companies.

Tom Rodgers joined the board in November 2005, and is a partner at Advanced Technology Ventures (ATV), where he focuses on the medical device and life sciences sectors. Prior to joining ATV, Mr. Rodgers had 13 years of operating experience in the healthcare industry, most recently serving as vice president of corporate strategy and business development at McKesson Corporation, a Fortune 15 company in the healthcare IT and pharmaceutical services industries. Prior to joining McKesson, Mr. Rodgers was the director of strategy for iMcKesson. Prior to that, he managed sales and oversaw healthcare strategy for FitLinxx, a venture-backed startup that pioneered the fitness and rehab intelligence technology market. His management background also includes marketing roles at Genentech and five years consulting at The Wilkerson Group. Mr. Rodgers holds an M.B.A. from the Wharton School and a B.A. from the University of Pennsylvania.

Zubeen Shroff has been a board member since November 2005. He is a managing partner at Galen Partners, an established late-stage healthcare private equity firm. Over the firm's 20-year history, the group has provided expansion capital to more than 70 companies, garnering more than $10 billion in market value. Several of these companies have become important players in their industry segment, including Dow Pharma Sciences, Eduneering, Encore Medical, JDS Pharmaceuticals, Lumenos, MedAssets, MiniMed, National Rehab Equipment, Ocular Sciences, and Pyxis. Mr. Shroff started his healthcare industry career with Schering-Plough in 1989 and when he left was head of their French subsidiary's biotech business group, which commercialized Alpha-Interferon. From 1993 to 1997, Mr. Shroff worked as a principal at The Wilkerson Group, a leading provider of management consulting services to the healthcare industry. Currently, he serves on the boards of several of Galen's privately held companies. Mr. Shroff received his M.B.A. from Wharton and is a founding board member of The Wharton Private Equity Network. Additionally, he is Vice Chairman of the Board of Directors at Westchester Medical Center, and Chairman of its foundation. He is also a member of Boston University's Medical School Advisory Board.

Dirk Soenksen is president and futurist of Aperio. He has more than 20 years of experience in all aspects of corporate management, previously as the president and CEO of Aperio, a role he assumed for more than 12 years after founding the company. Prior to founding Aperio, he was involved in three prior start-up ventures, including as vice president/GM at Applied Spectral Imaging, where he was instrumental in raising both private and venture capital. Prior to that, Mr. Soenksen spent six years in product development at GEC-Marconi. He has a proven record of identifying markets for new technologies and holds a number of patents related to microscope-based diagnostics.